First publicly listed company to actively investigate psilocybin’s potential impact on longevity NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the launch of a new psilocybin longevity research initiative in collaboration with leading researchers in South Africa. This program positions Psyence BioMed as t ...

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced it had established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs. This is a significant achievement for the Company as it prepa ...

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Psyence BioMed (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that, through its strategic investment in PsyLabs, it is now the only publicly listed psychedelics company with active operations and manufacturing capabilities based in Africa – the natural and original source of ibogaine. Derived from the Tabernanthe iboga shrub nat ...

RT 𝖒𝖎𝖗𝖆𝖌𝖊 (@miragemunny)bryan: “i’m really interested in the potential psilocybin might hold for longevity, how much do you guys think i should take to try it out?”bryan’s team: “definitely 5 grams” https://t.co/soR0F28btP ...

Core Insights - Psyence Biomedical Ltd. has made a follow-on investment of USD 3,500,000 in PsyLabs, enhancing its supply chain for psychedelic compounds [1][2] - This investment follows a previous investment of USD 500,000 in April 2025, indicating a strong commitment to securing high-quality, GMP-grade psychedelic ingredients [2][3] - The CEO of Psyence BioMed emphasized the strategic importance of this investment in building a fully integrated company focused on sustainable and scalable production [3] Company Overview - Psyence Biomedical Ltd. is a biopharmaceutical company specializing in nature-derived psilocybin and ibogaine therapies aimed at addressing unmet mental health needs [7] - It is the first life sciences biotechnology company focused on developing non-synthetic psychedelic medicine to be listed on Nasdaq [7] - The company aims to create safe, effective, and FDA-approved treatments for a range of mental health disorders [7] Partnership and Production - PsyLabs is recognized as a leading producer of purified psychedelic active pharmaceutical ingredients (APIs) and is federally licensed to cultivate and export various psychedelic compounds [9] - The partnership between Psyence BioMed and PsyLabs is strengthened through this investment, positioning Psyence as a leader in the emerging psychedelic therapeutics sector [5] - PsyLabs operates a state-of-the-art facility in Southern Africa, utilizing the region's botanical heritage under strict ethical and sustainable practices [4][10] Strategic Goals - The investment aims to secure a reliable supply of premium psychedelic compounds for Psyence BioMed's clinical research programs, ensuring long-term value for investors [2][3] - The company is focused on building a responsible global supply chain, which is crucial for advancing its clinical pipeline and commercial opportunities [3][5]

Research Focus - The study explores how religious clergy experience and interpret the effects of psilocybin, the active ingredient in magic mushrooms [1] Experimental Design - An experimental study investigated the effects of psilocybin on religious clergy [1]

Core Viewpoint - Red Light Holland has successfully shipped its naturally occurring psilocybin from its Netherlands facility to Irvine Labs in California, marking a significant milestone in their partnership and advancing their goal of developing microdosing capsules for global distribution [2][4][5]. Group 1: Shipment and Partnership - The shipment of psilocybin was made possible through the approval of a United States Controlled Substances import permit and the securing of a DEA quota [2][3]. - This first global shipment represents a groundbreaking milestone in the collaboration between Red Light Holland and Irvine Labs, with potency testing and shelf life extension protocols currently underway [3][5]. Group 2: Product Development and Research - The partnership aims to develop a commercialized and standardized psilocybin product that can be legally sold in emerging markets and utilized in government-funded pilot programs and clinical trials in the United States [5]. - Red Light Holland is focused on overcoming challenges in product development and manufacturing by implementing proprietary preservation technology to maintain the integrity of natural compounds while extending product shelf life [6]. Group 3: Future Plans and Capacity - Irvine Labs has the capacity for larger shipments under its existing 2025 DEA quota, allowing for the scaling of research and development efforts following the initial shipment [7]. - The companies plan to conduct comprehensive potency testing and shelf life extension testing of the delivered psilocybin materials, with future larger shipments already being planned [11].

Psychedelic Medicine - Psychedelic medicine 行业关注 psilocybin（一种迷幻蘑菇中的活性成分）的潜力，这得益于最近的一项研究 [1] - Ibogaine（一种从非洲灌木 Iboga 中提取的物质）也被 Psychedelic medicine 行业关注，因为各州正在努力批准相关药物 [1]